Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics, Inc. (BDTX)
:BDTX
BDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.59 - $7.66
Previous CloseN/A
Volume170.82K
Average Volume (3M)5.27M
Market Cap
$100.86M
Enterprise Value$156.13M
Total Cash (Recent Filing)$36.44M
Total Debt (Recent Filing)$22.19M
Price to Earnings (P/E)―
Beta3.60
Next Earnings
May 07, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding56,662,224
10 Day Avg. Volume14,852,729
30 Day Avg. Volume5,273,086
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)33.05
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.99
Forecast
1Y Price Target
$13.50Price Target Upside703.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Black Diamond Therapeutics News
PremiumMarket News
3 Penny Stocks to Watch Now, 3/20/25
PremiumCompany Announcements
Black Diamond Therapeutics Partners with Servier for BDTX-4933
PremiumCompany Announcements
Black Diamond Therapeutics Reports 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Cash ReservesBlack Diamond ended 2Q24 with approximately $112.7M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 4Q25.
Clinical DevelopmentBDTX-1535 has shown robust activity in both C797S and PACC non-classical EGFR+ NSCLC with objective response rates of 40% and 44%, which are competitive with alternative non-targeted therapies.
Financial PerformanceBlack Diamond reported its 3Q24 financial results, recording a net loss of $0.28 per share, narrower than the prior estimated net loss of $0.37 per share, predominantly attributed to lower-than-anticipated operating expenses.
Safety ProfileThe safety profile of BDTX-1535 is consistent with approved EGFR TKI class of drugs, with no cases of severe side effects like G3/4 diarrhea or off-target effects.
Bears Say
Clinical RisksNegative efficacy data for BDTX-1535 or BDTX-4933 and a poorer than expected efficacy or safety profile for these drugs are significant risks.
RisksRisks include negative efficacy data for BDTX-1535 or BDTX-4933 and poorer than expected efficacy or safety profiles.
---
Ownership Overview
19.47% Insiders
17.79% Mutual Funds
0.24% Other Institutional Investors
55.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BDTX FAQ
What was Black Diamond Therapeutics, Inc.’s price range in the past 12 months?
Black Diamond Therapeutics, Inc. lowest stock price was $1.59 and its highest was $7.66 in the past 12 months.
What is Black Diamond Therapeutics, Inc.’s market cap?
Black Diamond Therapeutics, Inc.’s market cap is $100.86M.
When is Black Diamond Therapeutics, Inc.’s upcoming earnings report date?
Black Diamond Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 42 days.
How were Black Diamond Therapeutics, Inc.’s earnings last quarter?
Black Diamond Therapeutics, Inc. released its earnings results on Mar 06, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.035.
Is Black Diamond Therapeutics, Inc. overvalued?
According to Wall Street analysts Black Diamond Therapeutics, Inc.’s price is currently Undervalued.
Does Black Diamond Therapeutics, Inc. pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
What is Black Diamond Therapeutics, Inc.’s EPS estimate?
Black Diamond Therapeutics, Inc.’s EPS estimate is 0.05.
How many shares outstanding does Black Diamond Therapeutics, Inc. have?
Black Diamond Therapeutics, Inc. has 56,662,224 shares outstanding.
What happened to Black Diamond Therapeutics, Inc.’s price movement after its last earnings report?
Black Diamond Therapeutics, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went down -1.053%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BDTX
---
Black Diamond Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (703.57% Upside)
$13.50 (703.57% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 555.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.43%
12-Months-Change
Fundamentals
Return on Equity
-69.67%
Trailing 12-Months
Asset Growth
-22.66%
Trailing 12-Months
Company Description
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
---
BDTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(703.57% Upside)
Technical Analysis
Blueprint Medicines
―
Kura Oncology
―
Revolution Medicines
―
Zentalis Pharmaceuticals
―
Best Analysts Covering BDTX
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-24.11%
assigned a buy rating 6 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -24.11% per trade.
---